Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies

Abstract

The combination of riluzole with sorafenib seems potent in suppressing tumor proliferation in vitro and in vivo in GRM1-expressing melanoma cells regardless of B-RAF genotype and may be a viable therapeutic clinical combination.